BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24330204)

  • 1. Transcatheter patent foramen ovale closure versus medical therapy for cryptogenic stroke: a meta-analysis of randomized clinical trials.
    Riaz IB; Dhoble A; Mizyed A; Hsu CH; Husnain M; Lee JZ; Lotun K; Lee KS
    BMC Cardiovasc Disord; 2013 Dec; 13():116. PubMed ID: 24330204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack.
    Li J; Liu J; Liu M; Zhang S; Hao Z; Zhang J; Zhang C
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009938. PubMed ID: 26346232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis.
    Khan AR; Bin Abdulhak AA; Sheikh MA; Khan S; Erwin PJ; Tleyjeh I; Khuder S; Eltahawy EA
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1316-23. PubMed ID: 24139929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials.
    Rengifo-Moreno P; Palacios IF; Junpaparp P; Witzke CF; Morris DL; Romero-Corral A
    Eur Heart J; 2013 Nov; 34(43):3342-52. PubMed ID: 23847132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PFO closure vs. medical therapy in cryptogenic stroke or transient ischemic attack: a systematic review and meta-analysis.
    Ntaios G; Papavasileiou V; Makaritsis K; Michel P
    Int J Cardiol; 2013 Oct; 169(2):101-5. PubMed ID: 24041984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
    Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
    JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percutaneous Closure of Patent Foramen Ovale in Patients with Cryptogenic Stroke - An Updated Comprehensive Meta-Analysis.
    Sitwala P; Khalid MF; Khattak F; Bagai J; Bhogal S; Ladia V; Mukherjee D; Daggubati R; Paul TK
    Cardiovasc Revasc Med; 2019 Aug; 20(8):687-694. PubMed ID: 30282597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patent foramen ovale closure versus medical therapy for prevention of recurrent cryptogenic embolism: updated meta-analysis of randomized clinical trials.
    Alushi B; Lauten A; Cassese S; Colleran R; Schüpke S; Rai H; Schunkert H; Meier B; Landmesser U; Kastrati A
    Clin Res Cardiol; 2018 Sep; 107(9):788-798. PubMed ID: 29644412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness and clinical efficacy of patent foramen ovale closure as compared to medical therapy in cryptogenic stroke patients: A detailed cost analysis and meta-analysis of randomized controlled trials.
    Pickett CA; Villines TC; Resar JR; Hulten EA
    Int J Cardiol; 2018 Dec; 273():74-79. PubMed ID: 30119914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patent foramen ovale closure vs medical therapy for stroke prevention: meta-analysis of randomized trials and review of heterogeneity in meta-analyses.
    Udell JA; Opotowsky AR; Khairy P; Silversides CK; Gladstone DJ; O'Gara PT; Landzberg MJ
    Can J Cardiol; 2014 Oct; 30(10):1216-24. PubMed ID: 25154803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis of transcatheter closure of patent foramen ovale versus medical therapy for prevention of recurrent thromboembolic events in patients with cryptogenic cerebrovascular events.
    Pineda AM; Nascimento FO; Yang SC; Kirtane AJ; Sommer RJ; Beohar N
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):968-75. PubMed ID: 23832613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of patent foramen ovale closure or medical therapy after cryptogenic stroke: A meta-analysis of randomized trials.
    Abdelaziz HK; Saad M; Abuomara HZ; Nairooz R; Pothineni NVK; Madmani ME; Roberts DH; Mahmud E
    Catheter Cardiovasc Interv; 2018 Jul; 92(1):176-186. PubMed ID: 29726616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percutaneous closure of patent foramen ovale for cryptogenic stroke: a meta-analysis of randomized controlled trials.
    Kwong JS; Lam YY; Yu CM
    Int J Cardiol; 2013 Oct; 168(4):4132-8. PubMed ID: 23890879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke.
    Wiktor DM; Carroll JD
    Circ Cardiovasc Interv; 2018 Mar; 11(3):e004152. PubMed ID: 29870380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percutaneous closure versus medical therapy alone for cryptogenic stroke patients with a patent foramen ovale: meta-analysis of randomized controlled trials.
    Pickett CA; Villines TC; Ferguson MA; Hulten EA
    Tex Heart Inst J; 2014 Aug; 41(4):357-67. PubMed ID: 25120387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of transcatheter closure versus medical therapy for patent foramen ovale in prevention of recurrent neurological events after presumed paradoxical embolism.
    Agarwal S; Bajaj NS; Kumbhani DJ; Tuzcu EM; Kapadia SR
    JACC Cardiovasc Interv; 2012 Jul; 5(7):777-89. PubMed ID: 22814784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcatheter patent foramen ovale closure versus standard medical therapy for prevention of recurrent stroke: Updated Meta-analysis with an importance on shunt size.
    Patel K; Doshi R; Goyal H; Shah P; Meraj P
    Eur J Intern Med; 2018 Nov; 57():e31-e33. PubMed ID: 30146180
    [No Abstract]   [Full Text] [Related]  

  • 18. Transcatheter Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke: A Meta-Analysis of Randomized Controlled Trials.
    Darmoch F; Al-Khadra Y; Soud M; Fanari Z; Alraies MC
    Cerebrovasc Dis; 2018; 45(3-4):162-169. PubMed ID: 29597192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percutaneous closure versus medical therapy for stroke with patent foramen Ovale: a systematic review and meta-analysis.
    Zhang XL; Kang LN; Wang L; Xu B
    BMC Cardiovasc Disord; 2018 Mar; 18(1):45. PubMed ID: 29499641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Net clinical benefit of patent foramen ovale closure in patients with cryptogenic stroke: Meta-analysis and meta-regression of randomized trials.
    Pasceri V; Pelliccia F; Bressi E; Mantione L; Gaudio C; Speciale G; Mehran R; Dangas GD; Patti G
    Int J Cardiol; 2018 Sep; 266():75-80. PubMed ID: 29887476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.